CRIPTO3 and Huntington disease: Inhibition of synaptic elimination through administration of a therapeutic C1q function-blocking antibody (ANX-M1, Annexon Biosciences) or genetic ablation of microglial complement receptor 3 (CR3/ITGAM) reduces loss of corticostriatal synapses and improves visual discrimination learning and cognitive flexibility impairments at early stages of disease progression in HD models.